TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Eva Giné et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.